Asthalin

# Asthalin (Salbutamol / Albuterol) ## Overview - **Classification**: Short-acting beta-2 adrenergic agonist (SABA). - **Mechanism**: Selectively stimulates beta-2 adrenergic receptors in bronchial smooth muscle, leading to bronchodilation. ## Primary Indications 1. **Acute Bronchospasm**: Relief of symptoms in asthma and COPD. 2. **Exercise-Induced Bronchospasm (EIB) Prevention**: Prophylaxis before activity. 3. **Acute Asthma Exacerbation**: As a rescue medication. ## Adult Dosing ### Standard Dosing **Acute Bronchospasm / Asthma Exacerbation** - **Dose**: **2 inhalations** (90 mcg/actuation) - **Frequency**: Every 4-6 hours as needed (PRN) - **Route**: Oral inhalation (Metered Dose Inhaler - MDI) - **Special Consideration**: For severe exacerbations, **4-8 inhalations** every 20 minutes for up to 4 hours, then every 1-4 hours PRN. **Acute Bronchospasm / Asthma Exacerbation (Nebulization)** - **Dose**: **2.5 mg** - **Frequency**: Every 4-6 hours as needed (PRN) - **Route**: Nebulization (over 5-15 minutes) - **Special Consideration**: For severe exacerbations, **2.5-5 mg** every 20 minutes for 3 doses, then 2.5-10 mg every 1-4 hours PRN. **Prevention of Exercise-Induced Bronchospasm** - **Dose**: **2 inhalations** (90 mcg/actuation) - **Frequency**: 15-30 minutes before exercise - **Route**: Oral inhalation (MDI) ### Dose Adjustments - **Renal Impairment**: No specific dose adjustment needed for inhaled formulations. - **Hepatic Impairment**: No specific dose adjustment needed for inhaled formulations. - **Elderly Patients**: No specific dose adjustment, but monitor closely for adverse effects (e.g., tremor, tachycardia). ## Pediatric Dosing ### Neonates (0-28 days) - **Dose**: Not routinely recommended for general use in this age group. - **Special Notes**: Use with extreme caution and only under strict medical supervision for specific indications. Specialist consultation required. ### Infants (1-12 months) **Acute Bronchospasm / Asthma Exacerbation** - **Dose**: **2 puffs** (90 mcg/puff) via MDI with spacer - **Frequency**: Every 4-6 hours as needed (PRN) - **Route**: Oral inhalation - **Maximum**: **2 puffs** per dose initially. In acute settings, may use up to **4-6 puffs** under medical supervision. **Acute Bronchospasm / Asthma Exacerbation (Nebulization)** - **Dose**: **1.25-2.5 mg** (0.05-0.15 mg/kg for very young, minimum 1.25 mg) - **Frequency**: Every 4-6 hours as needed (PRN) - **Route**: Nebulization - **Maximum**: **2.5 mg** per dose. ### Children (1-12 years) **Acute Bronchospasm / Asthma Exacerbation** - **Dose**: **2 inhalations** (90 mcg/actuation) via MDI with spacer - **Frequency**: Every 4-6 hours as needed (PRN) - **Route**: Oral inhalation - **Maximum**: In acute asthma, **4-8 inhalations** every 20 minutes for 3 doses, then every 1-4 hours PRN. **Acute Bronchospasm / Asthma Exacerbation (Nebulization)** - **Dose**: **2.5 mg** - **Frequency**: Every 4-6 hours as needed (PRN) - **Route**: Nebulization - **Maximum**: In acute asthma, **2.5-5 mg** every 20 minutes for 3 doses, then every 1-4 hours PRN. Max **10 mg/hour**. **Prevention of Exercise-Induced Bronchospasm** - **Dose**: **2 inhalations** (90 mcg/actuation) via MDI with spacer - **Frequency**: 15-30 minutes before exercise - **Route**: Oral inhalation ### Adolescents (13-18 years) - **Dose**: Treat as adult dosing. - **Maximum**: Follow adult maximum doses. ## Safety Information ### Contraindications - **Absolute**: Hypersensitivity to salbutamol or any component. - **Relative**: Tachyarrhythmias, severe uncontrolled hypertension. ### Common Adverse Effects - **Very Common (>10%)**: Tremor, headache. - **Common (1-10%)**: Tachycardia, palpitations, muscle cramps, dizziness, dry mouth, throat irritation. - **Serious but Rare**: Paradoxical bronchospasm, severe hypokalemia, cardiac arrhythmias (e.g., atrial fibrillation), myocardial ischemia. ### Key Drug Interactions - **Non-selective Beta-blockers (e.g., Propranolol)**: Can block bronchodilator effect; avoid co-administration. - **Diuretics (Thiazide, Loop)**: Increased risk of hypokalemia. Monitor serum potassium. - **MAOIs / TCAs**: Increased risk of cardiovascular adverse effects. Use with caution. - **Other Sympathomimetics**: May potentiate cardiovascular effects. ## Monitoring & Follow-up - **Before Treatment**: Baseline assessment of lung function (e.g., PEF, FEV1). - **During Treatment**: - Heart rate, blood pressure, respiratory rate. - Clinical response (symptom improvement, peak flow measurements). - Serum potassium (in severe exacerbations, high doses, or diuretic use). - **Clinical Signs**: Worsening bronchospasm, chest pain, palpitations, increased tremor. ## Clinical Pearls - 💡 **Rescue Inhaler**: Salbutamol is for rescue relief of acute symptoms, not for daily maintenance. - 💡 **Proper Technique**: Educate patients on correct MDI technique; use of a spacer improves drug delivery, especially in children. - 💡 **Overuse**: Increased frequency of use (>2 days/week, excluding EIB prevention) suggests inadequate asthma control and warrants reassessment of therapy. - 💡 **Paradoxical Bronchospasm**: If worsening wheezing occurs immediately after use, discontinue and seek medical attention. > **⚠️ Important**: This information is for educational purposes only. Always consult current prescribing information, local guidelines, and clinical judgment before prescribing.